Skip to main content
SpringerLink
Log in

Indications for Deep Brain Stimulation Therapy in Parkinson’s Disease

  • Chapter
  • First Online:
Surgery for Parkinson's Disease

  • 764 Accesses

Abstract

Parkinson’s disease (PD) is a degenerative movement disorder that affects 7 to 10 million people worldwide. The cardinal clinical features of PD are resting tremor, muscle rigidity, bradykinesia, and postural instability. These movement abnormalities are principally caused by death of dopamine-producing neurons in the substantia nigra. Most patients in early-stage PD respond well to medical therapy, usually levodopa, which alleviates these cardinal symptoms by replacing dopamine. After years of levodopa therapy, however, many patients develop motor fluctuations and experience an increase in “off” time (periods of time where the benefits of medications are limited). Deep brain stimulation (DBS) therapy is a surgical treatment that dramatically improves motor fluctuations as well as the principal features of bradykinesia, tremor, and rigidity. Additionally, DBS can be used to treat medication-induced dyskinesias. Although DBS therapy does not slow the progression of PD, it has been proven to improve motor fluctuations and quality of life beyond what can be achieved with best medical therapy. Patient selection is critically important in order to obtain these significant benefits, and dopamine responsiveness is a key diagnostic test. Due to the heterogeneity of PD symptoms and the complexity of accurate diagnosis, a team process for patient selection should be used. In this chapter, we will review the indications and patient selection criteria for DBS therapy for Parkinson’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6):525–35.

    Article  PubMed  Google Scholar 

  2. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med. 2003;348(14):1356–64.

    Article  CAS  PubMed  Google Scholar 

  3. Dorsey ER, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–6.

    Article  CAS  PubMed  Google Scholar 

  4. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Gasser T. Usefulness of genetic testing in PD and PD trials: a balanced review. J Parkinsons Dis. 2015;5:209–15.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Warner TT, Schapira AH. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol. 2003;53(Suppl 3):S16–23. discussion S23–25

    Article  CAS  PubMed  Google Scholar 

  7. Selikhova M, et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain. 2009;132(Pt 11):2947–57.

    Article  CAS  PubMed  Google Scholar 

  8. Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol. 2014;71(4):499–504.

    Article  PubMed  Google Scholar 

  9. Movement Disorder Society Task Force on Rating Scales for Parkinson's, Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18(7):738–50.

    Article  Google Scholar 

  10. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–76.

    Article  CAS  PubMed  Google Scholar 

  11. Hauser RA, Auinger P, Parkinson Study G. Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov Disord. 2011;26(5):813–8.

    Article  PubMed  Google Scholar 

  12. Macleod AD, Taylor KS, Counsell CE. Mortality in Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1615–22.

    Article  PubMed  Google Scholar 

  13. Galvan A, Wichmann T. Pathophysiology of parkinsonism. Clin Neurophysiol. 2008;119(7):1459–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Lees AJ, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Mov Disord. 2015;30(1):19–36.

    Article  CAS  PubMed  Google Scholar 

  15. Olanow CW, Brundin P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov Disord. 2013;28(1):31–40.

    Article  CAS  PubMed  Google Scholar 

  16. Braak H, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197–211.

    Article  PubMed  Google Scholar 

  17. Halliday GM, McCann H. The progression of pathology in Parkinson's disease. Ann N Y Acad Sci. 2010;1184:188–95.

    Article  PubMed  Google Scholar 

  18. Cedarbaum JM, et al. Effect of supplemental carbidopa on bioavailability of L-dopa. Clin Neuropharmacol. 1986;9(2):153–9.

    Article  CAS  PubMed  Google Scholar 

  19. Nelson MV, et al. Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. Clin Neuropharmacol. 1989;12(2):91–7.

    Article  CAS  PubMed  Google Scholar 

  20. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969;280(7):337–45.

    Article  CAS  PubMed  Google Scholar 

  21. Olanow CW. Levodopa: effect on cell death and the natural history of Parkinson's disease. Mov Disord. 2015;30(1):37–44.

    Article  CAS  PubMed  Google Scholar 

  22. Fahn S, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498–508.

    Article  CAS  PubMed  Google Scholar 

  23. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci. 2008;9(9):665–77.

    Article  CAS  PubMed  Google Scholar 

  24. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–58.

    Article  CAS  PubMed  Google Scholar 

  25. Cilia R, et al. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(Pt 10):2731–42.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Parkinson Study G. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287(13):1653–61.

    Article  Google Scholar 

  27. Whone AL, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54(1):93–101.

    Article  CAS  PubMed  Google Scholar 

  28. American Academy of Neurology. Practice Parameter: Treatment of Parkinson Disease with Motor Fluctuations and Dyskinesia. 2006; Available from: aan.com/guidelines.

  29. Olanow CW, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–9.

    Article  CAS  PubMed  Google Scholar 

  30. Guridi J, Lozano AM. A brief history of pallidotomy. Neurosurgery. 1997;41(5):1169–80. discussion 1180-3

    Article  CAS  PubMed  Google Scholar 

  31. Speelman JD, Bosch DA. Resurgence of functional neurosurgery for Parkinson's disease: a historical perspective. Mov Disord. 1998;13(3):582–8.

    Article  CAS  PubMed  Google Scholar 

  32. DeLong MR, et al. The contribution of basal ganglia to limb control. Prog Brain Res. 1986;64:161–74.

    Article  CAS  PubMed  Google Scholar 

  33. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 1990;249(4975):1436–8.

    Article  CAS  PubMed  Google Scholar 

  34. Pollak P, et al. Effects of the stimulation of the subthalamic nucleus in Parkinson disease. Rev Neurol (Paris). 1993;149(3):175–6.

    CAS  Google Scholar 

  35. McCairn KW, Turner RS. Deep brain stimulation of the globus pallidus internus in the parkinsonian primate: local entrainment and suppression of low-frequency oscillations. J Neurophysiol. 2009;101(4):1941–60.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Brown P. Bad oscillations in Parkinson's disease. J Neural Transm Suppl. 2006;70:27–30.

    Google Scholar 

  37. Wingeier B, et al. Intra-operative STN DBS attenuates the prominent beta rhythm in the STN in Parkinson's disease. Exp Neurol. 2006;197(1):244–51.

    Article  PubMed  Google Scholar 

  38. Shimamoto SA, et al. Subthalamic nucleus neurons are synchronized to primary motor cortex local field potentials in Parkinson's disease. J Neurosci. 2013;33(17):7220–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Chiken S, Nambu A. Disrupting neuronal transmission: mechanism of DBS? Front Syst Neurosci. 2014;8:33.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Deuschl G, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896–908.

    Article  CAS  PubMed  Google Scholar 

  41. Weaver FM, et al. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology. 2012;79(1):55–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Odekerken VJ, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol. 2013;12(1):37–44.

    Article  PubMed  Google Scholar 

  43. Krack P, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 2003;349(20):1925–34.

    Article  CAS  PubMed  Google Scholar 

  44. Hamani C, et al. Bilateral subthalamic nucleus stimulation for Parkinson's disease: a systematic review of the clinical literature. Neurosurgery. 2005;56(6):1313–21. discussion 1321-4

    Article  PubMed  Google Scholar 

  45. Kleiner-Fisman G, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006;21(Suppl 14):S290–304.

    Article  PubMed  Google Scholar 

  46. Okun MS, et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol. 2009;65(5):586–95.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Limousin P, et al. Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. J Neurol Neurosurg Psychiatry. 1999;66(3):289–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Aviles-Olmos I, et al. Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach. J Neurol Neurosurg Psychiatry. 2014;85(12):1419–25.

    Article  PubMed  Google Scholar 

  49. Funkiewiez A, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004;75(6):834–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Weintraub D, et al. Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2013;84(10):1113–8.

    Article  PubMed  Google Scholar 

  51. Weintraub D, et al. Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord. 2015;30(2):121–7.

    Article  CAS  PubMed  Google Scholar 

  52. Tarsy D, et al. Progression of Parkinson's disease following thalamic deep brain stimulation for tremor. Stereotact Funct Neurosurg. 2005;83(5–6):222–7.

    Article  PubMed  Google Scholar 

  53. Bang Henriksen, M., et al., Surviving 10 years with deep brain stimulation for Parkinson's disease - a follow-up of 79 patients. Eur J Neurol, 2014. (in press).

    Google Scholar 

  54. Okun MS, et al. Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol. 2005;62(8):1250–5.

    Article  PubMed  Google Scholar 

  55. Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet. 2015;31(3):140–9.

    Article  CAS  PubMed  Google Scholar 

  56. Hughes AJ, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Schuepbach WM, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013;368(7):610–22.

    Article  CAS  PubMed  Google Scholar 

  58. Mestre TA, et al. Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better. Mov Disord. 2014;29(14):1751–6.

    Article  PubMed  Google Scholar 

  59. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427–42.

    Article  CAS  PubMed  Google Scholar 

  60. Bronstein JM, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011;68(2):165.

    Article  PubMed  Google Scholar 

  61. Castrioto A, et al. Mood and behavioural effects of subthalamic stimulation in Parkinson's disease. Lancet Neurol. 2014;13(3):287–305.

    Article  PubMed  Google Scholar 

  62. Massano J, Garrett C. Deep brain stimulation and cognitive decline in Parkinson's disease: a clinical review. Front Neurol. 2012;3:66.

    PubMed  PubMed Central  Google Scholar 

  63. Lang AE, et al. Deep brain stimulation: preoperative issues. Mov Disord. 2006;21(Suppl 14):S171–96.

    Article  PubMed  Google Scholar 

  64. Llebaria G, et al. Cut-off score of the Mattis dementia rating scale for screening dementia in Parkinson's disease. Mov Disord. 2008;23(11):1546–50.

    Article  PubMed  Google Scholar 

  65. Witt K, et al. Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson's disease. J Neurol Sci. 2011;310(1–2):261–6.

    Article  PubMed  Google Scholar 

  66. Daniele A, et al. Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2003;74(2):175–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Rughani AI, Hodaie M, Lozano AM. Acute complications of movement disorders surgery: effects of age and comorbidities. Mov Disord. 2013;28(12):1661–7.

    Article  PubMed  Google Scholar 

  68. Welter ML, et al. Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain. 2002;125(Pt 3):575–83.

    Article  CAS  PubMed  Google Scholar 

  69. Derost PP, et al. Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology. 2007;68(17):1345–55.

    Article  PubMed  Google Scholar 

  70. Follett KA, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010;362(22):2077–91.

    Article  CAS  PubMed  Google Scholar 

  71. Anderson VC, et al. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol. 2005;62(4):554–60.

    Article  PubMed  Google Scholar 

  72. Hartinger M, et al. Effects of medication and subthalamic nucleus deep brain stimulation on tongue movements in speakers with Parkinson's disease using electropalatography: a pilot study. Clin Linguist Phon. 2011;25(3):210–30.

    Article  PubMed  Google Scholar 

  73. Putzer M, Barry WJ, Moringlane JR. Effect of bilateral stimulation of the subthalamic nucleus on different speech subsystems in patients with Parkinson's disease. Clin Linguist Phon. 2008;22(12):957–73.

    Article  PubMed  Google Scholar 

  74. Krack P, Hariz MI. Deep brain stimulation in Parkinson's disease: reconciliation of evidence-based medicine with clinical practice. Lancet Neurol. 2013;12(1):25–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, University of Utah, Salt Lake City, UT, USA

    Andrea Brock & Paul House

  2. Department of Biology, Salt Lake Community College, Salt Lake City, UT, USA

    Melissa Hardy

Authors
  1. Andrea Brock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melissa Hardy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul House
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul House .

Editor information

Editors and Affiliations

  1. Hackensack Meridian School of Medicine at Seton Hall University, Nutley, NJ, USA

    Robert R. Goodman

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Brock, A., Hardy, M., House, P. (2019). Indications for Deep Brain Stimulation Therapy in Parkinson’s Disease. In: Goodman, R. (eds) Surgery for Parkinson's Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-23693-3_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-23693-3_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-23692-6

  • Online ISBN: 978-3-319-23693-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation